| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL18R1 |
| Uniprot No | Q13478 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-329aa |
| 氨基酸序列 | AESCTSRPHITVVEGEPFYLKHCSCSLAHEIETTTKSWYKSSGSQEHVEL NPRSSSRIALHDCVLEFWPVELNDTGSYFFQMKNYTQKWKLNVIRRNKHS CFTERQVTSKIVEVKKFFQITCENSYYQTLVNSTSLYKNCKKLLLENNKN PTIKKNAEFEDQGYYSCVHFLHHNGKLFNITKTFNITIVEDRSNIVPVLL GPKLNHVAVELGKNVRLNCSALLNEEDVIYWMFGEENGSDPNIHEEKEMR IMTPEGKWHASKVLRIENIGESNLNVLYNCTVASTGGTDTKSFILVRKAD MADIPGHVFTR |
| 预测分子量 | 62 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IL18R1重组蛋白的模拟参考文献示例(内容基于学术文献常见主题概括，建议通过学术数据库核实真实文献)：
---
1. **文献名称**: *"Recombinant IL18R1 protein modulates IL-18 signaling in inflammatory responses"*
**作者**: Smith A, et al.
**摘要**: 研究通过大肠杆菌系统表达重组IL18R1蛋白，分析其与IL-18配体的结合动力学，发现其免疫球蛋白样结构域对下游NF-κB信号通路的激活至关重要，为靶向IL-18通路的抗炎治疗提供依据。
2. **文献名称**: *"Structural characterization of recombinant IL18R1 and its role in autoimmune disorders"*
**作者**: Chen L, et al.
**摘要**: 利用X射线晶体学解析重组IL18R1胞外域结构，揭示其与IL-18结合的分子机制，并通过小鼠模型证明重组IL18R1-Fc融合蛋白可抑制胶原诱导性关节炎，提示其作为自身免疫疾病治疗剂的潜力。
3. **文献名称**: *"Functional analysis of IL18R1 variants using recombinant protein expression"*
**作者**: Tanaka K, et al.
**摘要**: 构建多种IL18R1突变体重组蛋白，发现某些单核苷酸多态性(SNPs)导致IL-18结合能力下降，与临床哮喘患者中IL-18信号减弱相关，为个体化免疫治疗提供新视角。
4. **文献名称**: *"Recombinant IL18R1 as a decoy receptor in cancer immunotherapy"*
**作者**: Wang Y, et al.
**摘要**: 开发可溶性重组IL18R1蛋白作为IL-18拮抗剂，在黑色素瘤模型中验证其通过阻断IL-18介导的促肿瘤炎症反应，显著抑制肿瘤生长并增强PD-1抗体疗效。
---
**注意**：以上内容为模拟概括，实际文献需通过PubMed、Web of Science或Google Scholar等平台检索关键词“IL18R1 recombinant protein”获取。
**Background of IL18R1 Recombinant Protein**
Interleukin-18 receptor 1 (IL18R1), also known as IL-1 receptor-related protein 1 (IL1Rrp1), is a key component of the interleukin-18 (IL-18) signaling pathway. It belongs to the interleukin-1 receptor (IL-1R) family and functions as a transmembrane receptor primarily expressed on immune cells, including T cells, natural killer (NK) cells, and macrophages. IL18R1 binds to its ligand, IL-18. a pro-inflammatory cytokine involved in innate and adaptive immune responses, such as promoting interferon-gamma (IFN-γ) production and Th1 cell differentiation.
Structurally, IL18R1 consists of three immunoglobulin (Ig)-like domains in its extracellular region, a transmembrane domain, and a cytoplasmic Toll/IL-1 receptor (TIR) domain critical for downstream signaling. Upon IL-18 binding, IL18R1 recruits the accessory protein IL18RAP (IL-18 receptor accessory protein) to form a functional receptor complex, activating NF-κB and MAPK pathways to regulate inflammatory responses.
Recombinant IL18R1 protein is engineered *in vitro* using expression systems (e.g., mammalian, insect, or bacterial cells) to produce soluble or membrane-bound forms for research and therapeutic applications. It often includes tags (e.g., Fc or His tags) for purification and detection. As a research tool, it aids in studying IL-18/IL18R1 interactions, screening inhibitors for inflammatory diseases, and analyzing mutations affecting receptor function. Therapeutically, soluble IL18R1 variants are explored as decoy receptors to neutralize IL-18 in autoimmune disorders, metabolic syndromes, or cancer.
Dysregulation of IL18R1 signaling is linked to pathologies like rheumatoid arthritis, asthma, and inflammatory bowel disease, highlighting its role as a biomarker or therapeutic target. Recombinant IL18R1 thus serves as a vital reagent for dissecting immune mechanisms and developing targeted therapies.
×
